News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

06/14/2017 | CureVac AG

CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

Patents granted for mRNA-based RSV vaccines as well as for vaccination of infants / newborns and elderly with mRNA-based vaccines such as Flu CureVac AG a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has been granted important patents claiming the use of mRNA-based prophylactic vaccines, significantly add...
05/02/2017 | CureVac AG

CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, today announced the appointment of Daniel Menichella as CEO of CureVac Inc., its Boston based U.S. subsidiary. Mr. Menichella, an experienced executive in the biotech-industry, will develop CureVac’s US organization with a clear focus on business an...
04/12/2017 | Exyte

M+W Group names new CEO for the Americas Region

Rick Whitney has been named CEO of M+W Group’s Americas Region and President of the company’s subsidiary M+W U.S. Inc. Whitney brings extensive industry expertise to his second stint at M+W Group, where he worked from 1997 to 2014.
04/12/2017 | Curetis GmbH

Curetis erweitert Aufsichtsrat und Medizinischen Beirat

Dr. Nils Clausnitzer für Aufsichtsratsmitgliedschaft nominiert; Dr. Melissa Miller in Medizinischen Beirat aufgenommen
03/29/2017 | Exyte

M+W Group Promotes Smart Lab Design at the Asia Pharma R&D Leaders Summit 2017

M+W Group was invited as a thought leadership company to participate in the Asia Pharma R&D Leaders Summit 2017, a key pharma R&D event in China, being held in Shanghai, China.
03/16/2017 | Exyte

M+W Group on a Successful Streak with Semiconductor Awards

Leading global high-tech engineering company, M+W Group is celebrating their recent successes in semiconductor projects with awards in both China and Taiwan.
03/02/2017 | Exyte

New leadership at M+W Group

Changes have been made to M+W Group's executive board. Dr Wolfgang Büchele will be the new CEO and Mr Roberto Penno will be the new COO.
02/14/2017 | Atriva Therapeutics GmbH

Atriva receives seed financing to develop its next generation influenza therapeutic

The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinica...
01/09/2017 | immatics biotechnologies GmbH

Amgen and immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Arrangement Combines Immatics’ XPRESIDENT® Technology and Amgen’s Proprietary Bispecific Antibody Platform. Immatics to Receive $30 Million Upfront and Potentially Over $1 Billion in Milestone Payments Plus Royalties.
12/06/2016 | Curetis GmbH

Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy

For the first time, evidence suggests the same vaccine formulation (RNAdjuvant®) may elicit similar potency in both cancer patients and healthy subjects. RNAdjuvant® found to induce IFNgamma release from PBMCs; critical for innate and adaptive immunity including Th1 type T-cell responses.
11/08/2016 | CureVac AG

CureVac Receives Broad Patent for RNAntibody® Technology

CureVac AG today announced that it has been granted a patent (patent No. EP2101823) by the European Patent Office providing broad patent protection for the Company’s RNAntibody® technology.
11/08/2016 | CureVac AG

CureVac Secures an Additional $29.5 Million From Two New Investors

Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte and Landeskreditbank Baden-Württemberg invest in CureVac‘s development of innovative drugs „made in Baden-Württemberg“

Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the treatment of virus diseases” (US Application 14/434,328) is intended. This patent will cover, a method of treating a subject having a viral infection caused by an influenza virus with neuraminidase i...
10/11/2016 | CureVac AG

CureVac Appoints Pierre Kemula as Chief Financial Officer

Mr. Kemula will join CureVac’s management board and will be responsible for leading the company’s financial and capital markets activities. CureVac AG, the most clinically advanced mRNA company, today announced the appointment of Pierre Kemula as Chief Financial Officer (CFO). Mr. Kemula will join CureVac’s management board and will be responsibl...
10/07/2016 | Eberhard Karls Universität Tübingen

How “dead” bacteria return to life

Tübingen researchers discover strict genetic timetable for resuscitation of dormant cells
07/18/2016 | CureVac AG

Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

CureVac AG, the most clinically advanced mRNA company, today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine. The study, titled, “Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity,” demonstrated a mechanistic insigh...

Atriva Therapeutics Completes Transfer of Co-Infection Patent

Atriva Therapeutics GmbH announces the acquisition of the co-infection patent (Application Nr: PCT/IB2015/053644) from the University of Muenster, Germany. This patent covers the beneficial and potentially lifesaving use of MEK inhibitors against co-infections of bacteria, including multi-resistant bacterial strains such as MRSA, which often occurs...